This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.
August 13, 2020
MSCopilot® development was selected for innovation support under the Innov'up Leader PIA program, jointly funded by the State and the Ile-de-France Regional Council and operated by Bpifrance.
This program will enable Ad Scientiam to continue accelerating MSCopilot® development, a CE-marked software medical device for real-world self-assessment by Multiple Sclerosis (MS) patients.
Ad Scientiam was selected by a jury of French and German experts for the French Healthcare Booster Germany program, aimed at developing our activities in Germany.
March 9, 2023
Ad Scientiam was selected by the Ile-de-France Regional Council under the PM'up program, as part of the #Leader strategy for innovation.
April 1, 2021
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
Talk to our experts and discover how our solutions integrate into your practice or studies.